Antidepressant-induced membrane trafficking regulates blood-brain barrier permeability
Open Access
- 30 May 2024
- journal article
- research article
- Published by Springer Nature in Molecular Psychiatry
- Vol. 29 (11) , 3590-3598
Abstract
As the most prescribed psychotropic drugs in current medical practice, antidepressant drugs (ADs) of the selective serotonin reuptake inhibitor (SSRI) class represent prime candidates for drug repurposing. The mechanisms underlying their mode of action, however, remain unclear. Here, we show that common SSRIs and selected representatives of other AD classes bidirectionally regulate fluid-phase uptake at therapeutic concentrations and below. We further characterize membrane trafficking induced by a canonical SSRI fluvoxamine to show that it involves enhancement of clathrin-mediated endocytosis, endosomal system, and exocytosis. RNA sequencing analysis showed few fluvoxamine-associated differences, consistent with the effect being independent of gene expression. Fluvoxamine-induced increase in membrane trafficking boosted transcytosis in cell-based blood-brain barrier models, while a single injection of fluvoxamine was sufficient to enable brain accumulation of a fluid-phase fluorescent tracer in vivo. These findings reveal modulation of membrane trafficking by ADs as a possible cellular mechanism of action and indicate their clinical repositioning potential for regulating drug delivery to the brain.Keywords
Funding Information
- National Natural Science Foundation of China (32070772)
This publication has 75 references indexed in Scilit:
- Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19JAMA, 2023
- Fluvoxamine for Outpatient Management of COVID-19 to Prevent HospitalizationJAMA Network Open, 2022
- Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19JAMA, 2020
- Drug repurposing for Alzheimer’s disease: Selective serotonin reuptake inhibitorsAlzheimer's & Dementia, 2020
- Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019Alzheimer's & Dementia, 2020
- The role of hepatic cytochrome P450s in the cytotoxicity of sertralineArchives of Toxicology, 2020
- Therapeutic Drug Monitoring of Antidepressants2018
- Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and AdolescentsJAMA Psychiatry, 2017
- Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders2017
- Clinical Implications of Imipramine Plasma Levels for Depressive IllnessArchives of General Psychiatry, 1977